President and Chief Executive Officer
Jeffrey A. Duchemin was appointed Chief Executive Officer on August 26, 2013. Mr. Duchemin assumed the additional roles of President on November 1, 2013 and Director on October 29, 2013. Prior to joining Harvard Bioscience, Mr. Duchemin spent 16 years with Becton Dickinson (“BD”) in progressive sales, marketing and executive leadership positions across BD’s three business segments; BD Medical Systems, BD Diagnostic Systems, and BD Biosciences. In October 2012, BD Biosciences Discovery Labware was acquired by Corning Life Sciences. Mr. Duchemin was a Global Business Director for Corning Life Sciences until his recent departure to Harvard Bioscience. Mr. Duchemin is a transformational leader with demonstrated business results. The depth of his experience spans across a broad range of life science research and medical device products resulting in growth on a global basis. Mr. Duchemin earned an M.B.A. from Southern New Hampshire University and a B.S. in accounting from the University of Massachusetts Dartmouth.
Chief Financial Officer
Kam Unninayar was appointed Chief Financial Officer (CFO) on November 26, 2018. Before joining Harvard Bioscience, Ms. Unninayar was CFO at Tetraphase Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company. Prior to that she spent more than eleven years at Thermo Fisher Scientific (NYSE: TMO) across multiple roles leading financial operations, corporate financial planning and analysis, finance for business strategy, and acquisitions and integrations. During her tenure there, Ms. Unninayar was Vice President Finance for the Customer Channels group, Laboratory Products and Services segment, and other businesses with revenues that ranged from $200 million to $4 billion. Earlier in her career, she held a variety of finance roles with increasing responsibilities at Fortune 500 consumer companies. Ms. Unninayar holds a Master of Science in Administration from Wichita State University and a Master of Finance and Control and Bachelor of Commerce from the University of Delhi, India.
Vice President and General Manager Physiology, Cell and Molecular Instruments
Mr. Sun was appointed VP and General Manager of Physiology, Cell and Molecular Instruments in February of 2017. He previously held the position of VP Commercial Operations since October 2015, and VP Strategic Marketing, Business Development and R&D since October 2013. Prior to joining Harvard Bioscience, he served as Vice President of Global Marketing and Americas Sales at Beaver-Visitec International, a company combining former ophthalmic business units from Becton, Dickinson & Company (BD) and Medtronic; in this role he led global marketing to develop and implement strategic marketing plans in target surgical markets. Prior to this, he served in progressive positions at BD, including Director of Global Marketing & U.S. Sales. Earlier, he served as Marketing Manager, Global Life Sciences Market & Greater China Region at Eli Lilly & Company’s eLilly Unit (now InnoCentive, Inc.). Mr. Sun, holds an M.B.A. from the MIT Sloan School of Management, a master of science degree in environmental science & engineering from Northeastern University and a bachelor of science degree in biochemistry from Peking University.
Vice President and General Manager, Electrophysiology
Mr. Boven was appointed VP and General Manager of the Electrophysiology Business Unit on February of 2017. In 1996, he and Andreas Möller co-founded Multi Channel Systems (MCS) where they were Chief Executive Officers. In October 2014, Harvard Bioscience acquired MCS and Mr. Boven became Managing Director, Sales, Marketing & Operations. Prior to founding MCS, Mr. Boven held progressive positions in the field of bioelectronics at Schaerfe System GmbH, Germany (now part of Roche Diagnostics). Mr. Boven holds a diploma in physics with a major in computational neuroscience from the University of Tübingen.
Seth C. Hertel
Vice President and General Manager – DSI
Seth C. Hertel was appointed VP and General Manager of Data Sciences International (DSI) in October of 2018. From 2016 to 2018 he served as Global Head of Sales for the Pharmaceutical Business Unit of Roquette Freres, a >€3B annual company that produces natural ingredients used in the Food, Industrial, and Pharmaceutical markets. Starting in 2004 through 2016, he spent two terms totaling almost ten years with Sigma-Aldrich (now Merck KGaA) in various positions, including three years in Singapore as the Regional Managing Director of Southeast Asia and Oceania and finally as the VP of Channel Management across the corporate enterprise. Mr. Hertel also brings preclinical CRO experience via his role as VP Early Development at Covance (now LabCorp) from 2011 through 2012. He started his career with Barnstead International (now Thermo Fisher) working in international management roles in both Latin America and Europe. Mr. Hertel graduated from the Global Executive M.B.A program with dual M.B.A. degrees from Columbia University and London Business School in 2006. He has an M.A. in Portuguese from University of Wisconsin – Madison as well as a B.A. in Political Science, also from Madison.
Russell J. Sylvia
Vice President, Global Human Resources
Russell J. Sylvia was appointed Vice President, Global Human Resources on August 6, 2018. Prior to joining Harvard Bioscience, he served as Vice President and Senior Director of Human Resources at Nypro Packaging Solutions, a global division of Jabil Circuit. Prior to Nypro, he spent 11 years in progressive, global positions with Covidien, until its acquisition by Medtronic in 2015. He has also previously held HR leadership roles with Thermo Fisher Scientific and Coca-Cola Enterprises. Mr. Sylvia earned a J.D. from New England School of Law, an M.B.A. from Bryant University, and a B.A. in Political Science from the University of Massachusetts, Dartmouth. He is also certified as a Senior Professional in Human Resources (SPHR) by the Human Resources Certification Institute and as a Senior Certified Professional (SHRM-SCP) by the Society for Human Resources Management.